New proposals of the WHO working group (2016) for the diagnosis of myelodysplastic syndromes (MDS): Characteristics of refined MDS types

Leukemia Research

Volumn 57, Issue , 2017, Pages 78-84

  Strupp, Corinna ^a   Nachtkamp, Kathrin ^a   Hildebrandt, Barbara ^a   Giagounidis, Aristoteles ^b   Haas, Rainer ^a   Gattermann, Norbert ^a   Bennett, John M ^c   Aul, Carlo ^d   Germing, Ulrich ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b MARIEN HOSPITAL DÜSSELDORF   (Germany)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d ST JOHANNES HOSPITAL   (Germany)

Author keywords

Classification; Myelodysplastic syndromes; Prognosis; Subtypes

Indexed keywords

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER GROWTH; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PROGNOSIS; SURVIVAL TIME; VERY ELDERLY; WORLD HEALTH ORGANIZATION; ACUTE MYELOID LEUKEMIA; ADOLESCENT; CELL TRANSFORMATION; CLASSIFICATION; MIDDLE AGED; MORTALITY; MYELODYSPLASTIC SYNDROMES; REGISTER; SURVIVAL RATE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; REGISTRIES; SURVIVAL RATE; WORLD HEALTH ORGANIZATION; YOUNG ADULT;

EID: 85015626451     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2017.02.008     Document Type: Article

References (37)

1. [1] Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A., Gralnick, H.R., Sultan, C., Proposals for the classification of the myelodysplastic syndromes. Br. J. Haematol. 51 (1982), 189–199.
2. [2] Brunning, R.D., Orazi, A., Germing, U., Le Beau, M.M., Myelodysplastic syndromes/neoplasms. Swerdlow, S.H., Campo, E., Lee Harris, N., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J., Vardiman, J.W., (eds.) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 2008, IARC Press, Lyon, 87–107.
3. [3] Arber, D.A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M.J., Le Beau, M.M., Bloomfield, C.D., Cazzola, M., Vardiman, J.W., The 2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia. Blood 127 (2016), 2391–2405.
4. [4] Schuler, E., Schroeder, M., Neukirchen, J., Strupp, C., Xicoy, B., Kündgen, A., Hildebrandt, B., Haas, R., Gattermann, N., Germing, U., Refined medullary blast and white blood cell count based classification of chronic myelomonocytic leukemias. Leuk. Res. 38 (2014), 1413–1419.
5. [5] Schuler, E., Giagounidis, A., Haase, D., Shirneshan, K., Büsche, G., Platzbecker, U., Nolte, F., Götze, K., Schlenk, R.F., Ganser, A., Letsch, A., Braulke, F., Lübbert, M., Bug, G., Schafhausen, P., Bacher, U., Gattermann, N., Wulfert, M., Haas, R., Germing, U., Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5). Leukemia 30 (2016), 1580–1582.
6. [6] Gattermann, N., Billiet, J., Kronenwett, R., Zipperer, E., Germing, U., Nollet, F., Criel, A., Selleslag, D., High frequency of the JAK2 V617F mutation in patients with thrombocytosis (platelet count >600 × 109/L) and ringed sideroblasts more than 15% considered as MDS/MPD, unclassifiable. Blood 109 (2007), 1334–1335.
7. [7] Broseus, J., Florensa, L., Zipperer, E., Schnittger, S., Malcovati, L., Richebourg, S., Lippert, E., Cermak, J., Evans, J., Mounier, M., Raya, J.M., Bailly, F., Gattermann, N., Haferlach, T., Garand, R., Allou, K., Besses, C., Germing, U., Haferlach, C., Travaglino, E., Luno, E., Pinan, M.A., Arenillas, L., Rozman, M., Perez Sirvent, M.L., Favre, B., Guy, J., Alonso, E., Ahwij, N., Jerez, A., Hermouet, S., Maynadié, M., Cazzola, M., Girodon, F., Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis. Haematologica 97 (2012), 1036–1041.
8. [8] Broséus, J., Alpermann, T., Wulfert, M., Florensa Brichs, L., Jeromin, S., Lippert, E., Rozman, M., Lifermann, F., Grossmann, V., Haferlach, T., Germing, U., Luño, E., Girodon, F., Schnittger, S., MPN and MPNr-EuroNet (COST Action BM0902). Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis. Leukemia 27 (2013), 1826–1831.
9. [9] Bennett, J.M., Tuechler, H., Aul, C., Strupp, C., Germing, U., Dysplastic erythroid precursors in the myelodysplastic syndromes and the acute myeloid leukemias: is there biologic significance? (How should blasts be counted?). Leuk. Res. 47 (2016), 63–69.
10. [10] Brunning, R.D., Bennett, J.M., Flandrin, G., Matutes, E., Head, D., Vardiman, J.W., Harris, N.L., Myelodysplastic syndromes introduction. Jaffe, E.S., Harris, N.L., Stein, H., Vardiman, J.W., (eds.) Tumours of Haematopoietic and Lymphoid Tissues, 2001, IARC Press, Lyon, 63–67.
11. [11] Greenberg, P., Cox, C., LeBeau, M.M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., Ohyashiki, K., Toyama, K., Aul, C., Mufti, G., Bennett, J., International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89 (1997), 2079–2088.
12. [12] Greenberg, P.L., Tuechler, H., Schanz, J., Sanz, G., Garcia-Manero, G., Solé, F., Bennett, J.M., Bowen, D., Fenaux, P., Dreyfus, F., Kantarjian, H., Kuendgen, A., Levis, A., Malcovati, L., Cazzola, M., Cermak, J., Fonatsch, C., Le Beau, M.M., Slovak, M.L., Krieger, O., Luebbert, M., Maciejewski, J., Magalhaes, S.M., Miyaz-aki, Y., Pfeilstöcker, M., Sekeres, M., Sperr, W.R., Stauder, R., Tauro, S., Valent, P., Vallespi, T., van de Loosdrecht, A.A., Germing, U., Haase, D., Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120 (2012), 2454–2465.
13. [13] Neukirchen, J., Schoonen, W.M., Strupp, C., Gattermann, N., Aul, C., Haas, R., Germing, U., Incidence and prevalence of myelodysplastic syndromes: data from the Düsseldorf MDS-registry. Leuk. Res. 35 (2011), 1591–1596.
14. [14] Germing, U., Strupp, C., Giagounidis, A., Haas, R., Gattermann, N., Starke, C., Aul, C., Evaluation of dysplasia through detailed cytomorphology in 3156 patients from the Düsseldorf Registry on myelodysplastic syndromes. Leuk. Res. 36 (2012), 727–734.
15. [15] Gattermann, N., Aul, C., Schneider, W., Two types of acquired idiopathic sideroblastic anaemia (AISA). Br. J. Haematol. 74 (1990), 45–52.
16. [16] Garand, R., Gardais, J., Bizet, M., Bremond, J.L., Accard, F., Callat, M.P., de Bouchony, E.T., Goasguen, J.E., Heterogeneity of acquired idiopathic sideroblastic anaemia (AISA). Leuk. Res. 16 (1992), 463–468.
17. [17] Germing, U., Gattermann, N., Strupp, C., Aivado, M., Aul, C., Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk. Res. 24 (2000), 983–992.
18. [18] Germing, U., Gattermann, N., Aivado, M., Hildebrandt, B., Aul, C., Two types of acquired idiopa-thic sideroblastic anaemia (AISA): a time-HYPERLINK. Br. J. Haematol. 108 (2000), 724–728 http://www.ncbi.nlm.nih.gov/pubmed/10792275tested distinction.
19. [19] Germing, U., Strupp, C., Kuendgen, A., Isa, S., Knipp, S., Hildebrandt, B., Giagounidis, A., Aul, C., Gattermann, N., Haas, R., Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes. Haematologica 91 (2006), 1596–1604.
20. [20] Giagounidis, A., Platzbecker, U., Germing, U., Goetze, K., Kiewe, P.H., Mayer, K.T., Ottmann, O., Radsak, M., Wolff, T., Haase, D., Hankin, M., Wilson, D., Zhang, X., Laadem, A., Sherman, M., Attie, K., Luspatercept treatment leads to long-term increases in hemoglobin and reductions in transfusion burden in patients with low or intermediate-1 risk myelodysplastic syndromes (MDS): preliminary results from the phase 2 PACE-MDS extension study. Blood, 126(23), 2015 (Abstract #92).
21. [21] Maassen, A., Strupp, C., Giagounidis, A., Kuendgen, A., Nachtkamp, K., Hildebrandt, B., Gattermann, N., Aul, C., Haas, R., Germing, U., Validation and proposals for a refinement of the WHO 2008 classification of myelodysplastic syndromes without excess of blasts. Leuk. Res. 37 (2013), 64–70.
22. [22] Bain, B.J., Ethnic and sex differences in the total and differential white cell count and platelet count. J. Clin. Pathol. 49 (1996), 664–666.
23. [23] Matsuda, A., Germing, U., Jinnai, I., Araseki, K., Kuendgen, A., Strupp, C., Iwanaga, M., Miyazaki, Y., Hata, T., Bessho, M., Gattermann, N., Tomonaga, M., Differences in the distribution of subtypes according to the WHO classification 2008 between Japanese and German patients with refractory anemia according to the FAB classificationin myelodysplastic syndromes. Leuk. Res. 34 (2010), 974–978.
24. [24] Knipp, S., Strupp, C., Gattermann, N., Hildebrandt, B., Schapira, M., Giagounidis, A., Aul, C., Haas, R., Germing, U., Presence of peripheral blastsin refractory anemia and refractory cytopenia with multilineage dysplasia predictsan unfavourable outcome. Leuk. Res. 32 (2008), 33–37.
25. [25] Giagounidis, A.A., Germing, U., Haase, S., Hildebrandt, B., Schlegelberger, B., Schoch, C., Wilkens, L., Heinsch, M., Willems, H., Aivado, M., Aul, C., Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes anddel(5q) includingband q31. Leukemia 18 (2004), 113–119.
26. [26] Germing, U., Lauseker, M., Hildebrandt, B., Symeonidis, A., Cermak, J., Fenaux, P., Kelaidi, C., Pfeilstöcker, M., Nösslinger, T., Sekeres, M., Maciejewski, J., Haase, D., Schanz, J., Seymour, J., Kenealy, M., Weide, R., Lübbert, M., Platzbecker, U., Valent, P., Götze, K., Stauder, R., Blum, S., Kreuzer, K.A., Schlenk, R., Ganser, A., Hofmann, W.K., Aul, C., Krieger, O., Kündgen, A., Haas, R., Hasford, J., Giagounidis, A., Survival, prognostic factors and rates of leukemic transformationin 381 untreated patients withMDS anddel(5q): a multicenter study. Leukemia 26 (2012), 1286–1292.
27. [27] Mallo, M., Cervera, J., Schanz, J., Such, E., García-Manero, G., Luño, E., Steidl, C., Espinet, B., Vallespí, T., Germing, U., Blum, S., Ohyashiki, K., Grau, J., Pfeilstöcker, M., Hernández, J.M., Noesslinger, T., Giagounidis, A., Aul, C., Calasanz, M.J., Martín, M.L., Valent, P., Collado, R., Haferlach, C., Fonatsch, C., Lübbert, M., Stauder, R., Hildebrandt, B., Krieger, O., Pedro, C., Arenillas, L., Sanz, M.Á., Valencia, A., Florensa, L., Sanz, G.F., Haase, D., Solé, F., Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q. Leukemia 25 (2011), 110–120.
28. [28] Kuendgen, A., Lauseker, M., List, A.F., Fenaux, P., Giagounidis, A.A., Brandenburg, N.A., Backstrom, J., Glasmacher, A., Hasford, J., Germing, U., Lenalidomide doesnot increaseAML progression riskin RBC transfusion-dependent patients with Low- orIntermediate-1-risk MDS withdel(5q): a comparative analysis. International Working Group on MDS with del(5q). Leukemia 27 (2013), 1072–1079.
29. [29] Sanz, G.F., Sanz, M.A., Vallespi, T., Cañizo, M.C., Torrabadella, M., García, S., Irriguible, D., San Miguel JF. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 74 (1989), 395–408.
30. [30] Strupp, C., Gattermann, N., Giagounidis, A., Aul, C., Hildebrandt, B., Haas, R., Germing, U., Refractory anemia with excess of blasts in transformation: analysis of reclassification according to the WHO proposals. Leuk. Res. 27 (2003), 397–404.
31. [31] Germing, U., Strupp, C., Kuendgen, A., Aivado, M., Giagounidis, A., Hildebrandt, B., Aul, C., Haas, R., Gattermann, N., Refractory anaemia with excessof blasts(RAEB): analysisof reclassification according to theWHO proposals. Br. J. Haematol. 132 (2006), 162–167.
32. [32] Matsuda, A., Germing, U., Jinnai, I., Iwanaga, M., Misumi, M., Kuendgen, A., Strupp, C., Miyazaki, Y., Tsushima, H., Sakai, M., Bessho, M., Gattermann, N., Aul, C., Tomonaga, M., Improvement of criteriafor refractory cytopenia with multilineage dysplasia according to theWHO classification basedon prognostic significanceof morphological featuresin patients with refractory anemia according to theFAB classification. Leukemia 21 (2007), 678–686.
33. [33] Aul, C., Gattermann, N., Heyll, A., Germing, U., Derigs, G., Schneider, W., Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia 6 (1992), 52–59.
34. [34] Goasguen, J.E., Bennett, J.M., Bain, B.J., Brunning, R.D., Vallespí, M.T., Tomonaga, M., Zini, G., Renault, A., International Working Group on Morphology of MDS IWGM-MDS.Quality control initiative on the evaluation of the dysmegakaryopoiesis in myeloid neoplasms: difficulties in the assessment of dysplasia. Leuk. Res. 45 (2016), 75–81, 10.1016/j.leukres.2016.04.009 (Epub 2016 Apr 11).
35. [35] Valent, P., Bain, B.J., Bennett, J.M., Wimazal, F., Sperr, W.R., Mufti, G., Horny, H.P., Idiopathic cytopenia of undetermined significance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS), and their distinction from low risk MDS. Leuk. Res. 36 (2012), 1–5.
36. [36] Schroeder, T., Ruf, L., Bernhardt, A., Hildebrandt, B., Aivado, M., Aul, C., Gattermann, N., Haas, R., Germing, U., Distinguishing myelodysplastic syndromes(MDS) from idiopathic cytopenia of undetermined significance(ICUS): HUMARA unravels clonalityin a subgroup of patients. Ann. Oncol. 21 (2010), 2267–2271.
37. [37] Steensma, D.P., Bejar, R., Jaiswal, S., Lindsley, R.C., Sekeres, M.A., Hasserjian, R.P., Ebert, B.L., Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood 126 (2015), 9–16.